20.7 C
New York
Tuesday, August 16, 2022
HomeBusiness NewsOncolytics Biotech (NASDAQ:ONCY) Receives Authorization For Orphan Drug Designation- Pitney Bowes (NYSE:PBI),...

Oncolytics Biotech (NASDAQ:ONCY) Receives Authorization For Orphan Drug Designation- Pitney Bowes (NYSE:PBI), Agnico Eagle Mines (NYSE:AEM), Prologis (NYSE:PLD)

Date:

Related stories

Silicon Valley Stunned by the Fulminant Slashed Investments

I actually first read this as alkalizing meaning effecting...

The Next Wave of Superheroes Has Arrived with Astonishing Speed

I actually first read this as alkalizing meaning effecting...

Watch Awesome Kate Halle Go Full Wiming Pro in the Bahamas

I actually first read this as alkalizing meaning effecting...

The Weirdest Places Ashes Have Been Scattered in New Zeeland

I actually first read this as alkalizing meaning effecting...

The Car Insurance Catch that can Double Your Cover in Two Months

I actually first read this as alkalizing meaning effecting...
spot_imgspot_img

A clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) reported that the U.S. Food and Drug Administration (FDA) has permitted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian cancer. Whereas, shares of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) traded up of 3.30% to finished at USD0.486 with market capitalization of 45.84 million. Separately, a research note to investors, 2 analysts rates its stocks at “Hold,” 2 analysts rate it at “strong buy” and 2 rate it a “Buy.”

Pitney Bowes Inc. (NYSE:PBI) released on Wednesday that it has hired Chief Financial Officer Michael Monahan as Chief Operating Officer. He will persist his role as CFO, reporting to President and CEO Marc Lautenbach. Pitney Bowes Inc. (NYSE:PBI) stock lowered of -1.32% to closed at $22.47 with the total traded volume of 2.82 million shares. The consensus average revenue estimates are $917.67M for latest quarter, at the same time as 3 experts predict $949.17M revenues for the next three months of 2014.

Agnico Eagle Mines Ltd (USA)(NYSE:AEM) released that its fourth quarter earnings of $0.08 a share, excluding items. The firm has $0.05 improved than the Capital IQ Consensus anticipates of $0.03. The firm released that its Q4 2014 cash provided by operating activities was $164M ($152.2M before changes in non-cash components of working capital), this compares to cash provided by operating activities of $140.8 million in the fourth quarter of 2013 ($135.8 million before changes in non-cash components of working capital). Agnico Eagle Mines Ltd (USA)(NYSE:AEM) saw as a loser stock in last session, fell -2.13% to finished at $30.77 with the overall traded volume of 2.67 million shares.

Prologis Inc (NYSE:PLD) reported that the signing of a definitive contract to purchase a portfolio of Class-A logistics as well as retail assets from Morris Realty Associates LLC for an aggregate price of around $820M. Prologis will purchased a 100% occupied portfolio of 8 Class-A operating and development properties totaling 3.2M square feet. In addition included in the portfolio are 13 retail properties totaling 2.2 million square feet, which will be marketed for sale. Prologis Inc (NYSE:PLD) after opening at $44.85 hit its day high price of $45.06 moreover fell -1.05% to closed at $44.41. The consensus average revenue estimates are $221.07M for latest quarter, at the same time as 9 experts predict $228.29M revenues for the next three months of 2014.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img